Kilitch Drugs (India) Limited

NSEI:KILITCH Lagerbericht

Marktkapitalisierung: ₹6.0b

Kilitch Drugs (India) Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Mukund Mehta

Geschäftsführender

₹6.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts100.0%
Amtszeit als Geschäftsführer32.3yrs
Eigentum des Geschäftsführers7.1%
Durchschnittliche Amtszeit des Managementskeine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder8.4yrs

Jüngste Management Updates

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Sep 23
Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Recent updates

Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Jul 23
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Mar 05
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

Feb 02
Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Jan 30
We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Nov 17
Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Sep 23
Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Sep 08
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

May 05
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Jul 06
Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

Apr 08
Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

Mar 21
Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 13
Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Dec 03
Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

Aug 20
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jul 16
Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Mukund Mehta im Vergleich zu den Einnahmen von Kilitch Drugs (India) verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

₹126m

Mar 31 2024n/an/a

₹146m

Dec 31 2023n/an/a

₹146m

Sep 30 2023n/an/a

₹140m

Jun 30 2023n/an/a

₹117m

Mar 31 2023₹6m₹6m

₹104m

Dec 31 2022n/an/a

₹98m

Sep 30 2022n/an/a

₹85m

Jun 30 2022n/an/a

₹83m

Mar 31 2022₹6m₹6m

₹74m

Dec 31 2021n/an/a

₹52m

Sep 30 2021n/an/a

₹63m

Jun 30 2021n/an/a

₹62m

Mar 31 2021₹6mn/a

₹37m

Dec 31 2020n/an/a

₹17m

Sep 30 2020n/an/a

₹4m

Jun 30 2020n/an/a

-₹3m

Mar 31 2020₹6mn/a

₹8m

Vergütung im Vergleich zum Markt: MukundDie Gesamtvergütung ($USD71.92K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD38.34K).

Entschädigung vs. Einkommen: MukundDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Mukund Mehta (71 yo)

32.3yrs

Amtszeit

₹6,000,000

Vergütung

Mr. Mukund Prataprai Mehta, B.Com, LL B., serves as the Chairman and Managing Director at Kilitch Drugs (India) Limited and has been its Executive Director since May 12, 1992. Mr. Mehta served as the Compl...

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Mukund Mehta
Executive Chairman & MD32.3yrs₹6.00m7.09%
₹ 425.1m
Bhavin Mehta
Whole-time Director7yrs₹8.40m15.69%
₹ 940.4m
Mira Mehta
Whole Time Director9.8yrs₹2.40m5.23%
₹ 313.5m
Hemang Engineer
Independent & Non Executive Director16.3yrs₹25.00kkeine Daten
Vasudev Murti
Non-Executive Independent Director6.5yrs₹30.00kkeine Daten
Venkita Rajan
Independent Non-Executive Director6.3yrs₹5.00kkeine Daten

8.4yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: KILITCHDie Vorstandsmitglieder gelten als erfahren (8.2 Jahre durchschnittliche Amtszeit).